Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study (Q58235659)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

0 references

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Ching-Lung Lai

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

7

Man-Fung Yuen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

5

Kevin Sze-Hang Liu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

8

Henry Lik-Yuen Chan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

3

Vincent Wai-Sun Wong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Aric Josun Hui

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Grace Lai-Hung Wong

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

English

0 references

publication date

15 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

667-672

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307237

10.1136/GUTJNL-2014-307237

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24833635%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference